What is Moleculin Biotech, Inc. (MBRX) stock price today?

Moleculin Biotech, Inc. (MBRX) is currently trading at $0.44, up 4.25% today.

What is MBRX P/E ratio?

Moleculin Biotech, Inc.'s P/E ratio is -0.03. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MBRX return on equity (ROE)?

Moleculin Biotech, Inc.'s return on equity (ROE) is -816.56%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Moleculin Biotech, Inc.'s market cap?

Moleculin Biotech, Inc. has a market capitalization of $2.36M.

NASDAQ · Biotechnology

Moleculin Biotech, Inc. (MBRX) Stock

$0.44 +4.25% NASDAQ: MBRX Healthcare

Valuation

Metric	Value
Price	$0.44
Market Cap	$2.36M
P/E Ratio	-0.03
P/B Ratio	0.24
P/S Ratio	0.00
EPS (TTM)	$-28.42
52-Week High	$15.75
52-Week Low	$0.16
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-816.56%
ROA	-143.82%
ROCE	-245.24%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.03
Current Ratio	1.43

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-23.0M	$-31.0M	$-30.0M	$-27.0M	$-25.0M
Net Profit	$-16.0M	$-29.0M	$-30.0M	$-22.0M	$-34.0M
EPS	$-221.77	$-380.51	$-376.71	$-189.14	$-28.42
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$84.0M	$57.0M	$38.0M	$17.0M	$22.0M
Total Liabilities	$5.0M	$5.0M	$12.0M	$11.0M	$7.0M
Cash	$71.0M	$43.0M	$24.0M	$4.0M	$9.0M
Borrowings	$0	$0	$1.0M	$0	$0

Latest News

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment GlobeNewswire · Jul 6, 2026 MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance Stocktwits · Jun 30, 2026 Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control GlobeNewswire · Jun 30, 2026 Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML GlobeNewswire · Jun 5, 2026 Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$-28.0M	$-24.0M	$-24.0M	$-23.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$56.0M	$-28.0M	$-20.0M	$-19.0M	$5.0M
Free Cash Flow	$-19.0M	$-28.0M	$-24.0M	$-24.0M	$-23.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.14
FCF Yield	-976.12%
Quick Ratio	0.94
Interest Coverage	-370.18
Return 1Y	-85.31%
Return 3Y	-99.02%
Return 5Y	-99.81%

Ownership

Insiders Held0.63%

Institutions Held3.33%

Institutions Float Held3.35%

Institutional Holder	Shares	Report Date
Sabby Management, LLC	75,021	2026-03-31
Geode Capital Management, LLC	32,329	2026-03-31
Vanguard Capital Management LLC	13,869	2026-03-31
HRT Financial LP	13,739	2026-03-31
Vanguard Fiduciary Trust Co	6,072	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADAPAdaptimmune Therapeutics plc	$0.05	-3.00%	-0.16	$75.16M	0.00%
AIMDAinos, Inc.	$1.21	+0.00%	-0.54	$8.91M	0.00%
APLMApollomics Inc.	$21.50	-1.29%	-2.84	$47.22M	0.00%
ATHAAthira Pharma, Inc.	$6.75	-6.12%	-0.28	$26.62M	0.00%
BLRXBioLineRx Ltd.	$2.85	-2.45%	-1.36	$12.39M	0.00%

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is led by CEO Walter V. Klemp, publicly traded since 2016.

Moleculin Biotech, Inc. (MBRX) stock trades at $0.44 with a market capitalization of $2.36M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.24, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.16 and $15.75, and currently trades 97.2% below its 52-week high.

On profitability, Moleculin Biotech, Inc. generates a return on equity (ROE) of -816.56%, return on capital employed of -245.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides